Stimulation of articular cartilage repair in established arthritis by local administration of transforming growth factor-beta into murine knee joints.
A severe consequence of rheumatoid arthritis is depletion of proteoglycans (PGs) from articular cartilage leading to functional impairment of this tissue. We investigated whether local administration of anabolic factors (transforming growth factors-beta1 and -beta2 [TGF-beta1 and -beta2, respectively] and bone morphogenetic protein-2 (BMP-2) into joints could stimulate cartilage repair during arthritis. A unilateral arthritis was induced in mice by intra-articular injection of zymosan. Starting on Day 4 after the induction of arthritis, three injections of TGF-beta1 (200 ng) were given (Days 4, 6, and 8). On Day 11, articular cartilage PG synthesis was measured by 35S-sulfate incorporation, and histologic knee joint sections were prepared, which were used to analyze cartilage PG content by quantification of safranin O staining. Additionally, histologic sections were used to analyze inflammation and chondrophyte-formation. Local administration of TGF-beta1 did not modify inflammation but clearly stimulated PG synthesis and restored PG content of depleted cartilage. TGF-beta2 appeared to be as potent as TGF-beta1 in the stimulation of cartilage repair, and both TGF-beta isoforms also stimulated the formation of chondrophytes in this rodent model. In contrast to TGF-beta, three intra-articular injections with 200 ng BMP-2 did not stimulate the repair process. In summary, this study demonstrates for the first time that local administration of TGF-beta into arthritic joints stimulates the replenishment of PGs in depleted cartilage.
Glansbeek
H L
HL
Department of Rheumatology, University Hospital Nijmegen, The Netherlands.
van Beuningen
H M
HM
Vitters
E L
EL
van der Kraan
P M
PM
van den Berg
W B
WB
D000287:Administration, Topical; D053674:Aggrecans; D000818:Animals; D001168:Arthritis / Q000503:physiopathology*; D058578:Biglycan; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use; D002358:Cartilage, Articular / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D058575:Decorin; D016326:Extracellular Matrix Proteins; D007270:Injections, Intra-Articular; D007719:Knee Joint / Q000187:drug effects* / Q000503:physiopathology*; D037181:Lectins, C-Type; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011453:Prostaglandins / Q000096:biosynthesis; D011509:Proteoglycans / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000008:administration & dosage* / Q000627:therapeutic use; D014945:Wound Healing / Q000187:drug effects
C508320:Acan protein, mouse; D053674:Aggrecans; C546885:Bgn protein, mouse; D058578:Biglycan; C525719:Bmp2 protein, mouse; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; C546879:Dcn protein, mouse; D058575:Decorin; D016326:Extracellular Matrix Proteins; D037181:Lectins, C-Type; D011453:Prostaglandins; D011509:Proteoglycans; D012333:RNA, Messenger; D016212:Transforming Growth Factor beta